BiotechTube

Patritumab + Cetuximab + Cisplatin + Carboplatin + Placebo

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Head and Neck Neoplasms

Conditions

Head and Neck Neoplasms

Trial Timeline

Dec 22, 2015 → Feb 21, 2018

NCT ID
NCT02633800

About Patritumab + Cetuximab + Cisplatin + Carboplatin + Placebo

Patritumab + Cetuximab + Cisplatin + Carboplatin + Placebo is a phase 2 stage product being developed by Daiichi Sankyo for Head and Neck Neoplasms. The current trial status is terminated. This product is registered under clinical trial identifier NCT02633800. Target conditions include Head and Neck Neoplasms.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02633800Phase 2Terminated

Competing Products

20 competing products in Head and Neck Neoplasms

See all competitors
ProductCompanyStageHype Score
AFM24 + SNK01AffimedPhase 1/2
33
Cemiplimab + CetuximabEli LillyPhase 2
52
BB-401Benitec BiopharmaPhase 2
44
Placebo + LY2300559Eli LillyPhase 2
52
Gemcitabine + ACR-368Acrivon TherapeuticsPhase 2
44
Ketorolac + Prochlorperazine + DiphenhydramineAssertio HoldingsPhase 2
44
Ramucirumab + PembrolizumabEli LillyPhase 2
52
Ozuriftamab Vedotin + Pembrolizumab + Evalstotug (BA3071) + CetuximabBioAtlaPhase 2
44
Patritumab + Cetuximab + Cisplatin + CarboplatinDaiichi SankyoPhase 1
33
cevimeline hydrochlorideDaiichi SankyoPhase 3
77
Docetaxel + Erlotinib + ChemotherapyAstellas PharmaPhase 2
52
ErlotinibAstellas PharmaPhase 1
33
avelumab + Bempegaldesleukin + talazoparib + enzalutamideAstellas PharmaPhase 1/2
41
Ivermectin Lotion, 0.5% + SKLICE (ivermectin) Lotion, 0.5% + Vehicle of the Test productSun PharmaceuticalPhase 1
33
Drug Combination TherapySun PharmaceuticalPhase 2
52
Lenvatinib + Pembrolizumab + Docetaxel + Capecitabine + Paclitaxel + Cetuximab + LenvatinibEisaiPhase 2
52
E7050 + CetuximabEisaiPhase 1/2
41
Lenvatinib + Pembrolizumab + PlaceboEisaiPhase 3
77
Lenvatinib + Pembrolizumab + PlaceboEisaiPhase 3
77
Aricept (donepezil hydrochloride)EisaiPhase 2
52

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85